The retailer says it is testing the technology in one market before making any long-term decisions about nationwide use.
Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of patients with relapsed or ...